OSCR — Oscar Health Inc. stock price and chart

Share this page

OSCR

$31.89-4.72%

as of close, Oct 16, 2026

☾ AH $31.89 -4.72%

Oscar Health Inc.Stock · HealthcareRussell 2000 0.2%US Stock Market 0.009%Russell 3000 0.009%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Mar 5, 2021

VolumeEEEE

20212022202320252026

5.010.015.020.025.030.035.00100.0M$31.89

2026-10-16

Price$31.89

MA20$31.26

MA50$25.91

Vol5.7M

What would $1,000 invested in OSCR be worth today? →

OSCR returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $31.89
YTD price return: +121.92%
YTD total return: +121.92%
Next earnings: Nov 5, 2026 · Before open
Market cap: 9.8B2021-03 2.4B2026-10 9.8B+312.1% over the window
Enterprise value: 6.3B
Shares outstanding: 308.6M2019-12 28.8M2026-06 308.6M+971.2% over the window
52W low: $10.69
52W high: $35.01
From 52W high: -8.91%
From 52W low: +198.32%
52W range: 87%

Volume

Rel volume: 1.06×
30D volume: 5.4M
30D $ vol: 172M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1M0 insider-days of buying (no priced lot) and 1 of selling ($806K) in the last 30 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$806K
Insider net 3M0 insider-days of buying (no priced lot) and 9 of selling ($26.8M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$26.8M
Insider net 1Y1 insider-day of buying ($11.9M) and 31 of selling ($142.4M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$130.5M

Form 4 transactions by trade date, as filed; latest on file 2026-09-18.

Fundamentals

Sales (ttm): 15.3B2019-12 488.2M2026-06 15.3B+3037.9% over the window
Sales/share: $49.632019-12 $16.942026-06 $49.63+192.9% over the window
EPS (ttm): $1.832019-12 -$9.062026-06 $1.83-120.2% over the window
FCF (ttm): 4.4B2019-12 -191.4M2026-06 4.4B-2388.8% over the window
FCF/share: $14.192019-12 -$6.642026-06 $14.19-313.7% over the window
Book value/share: $6.652019-12 -$32.802026-06 $6.65-120.3% over the window
Net margin: 3.60%2019-12 -53.5%2026-06 3.6%-106.7% over the window
ROE: 26.84%2021-03 -22.3%2026-06 26.8%-220.2% over the window
ROA: 4.91%2020-12 -17.9%2026-06 4.9%-127.4% over the window
Debt / equity: 0.21×2021-03 0.002026-06 0.21
Current ratio: 1.082020-12 1.122026-06 1.08-3.9% over the window

Growth (CAGR, ttm) · 10Y

Sales: +42.85%2025-06-30 → 2026-06-3010.7B → 15.3B (+42.8% total)+45.57%2023-06-30 → 2026-06-305B → 15.3B (+208.5% total)+77.94%2021-03-31 → 2026-06-30744.1M → 15.3B (+1958.7% total)n/a
FCF: +264.83%2025-06-30 → 2026-06-301.2B → 4.4B (+264.5% total)+205.48%2023-06-30 → 2026-06-30153.5M → 4.4B (+2752.8% total)+56.50%2021-03-31 → 2026-06-30417.4M → 4.4B (+949.2% total)n/a
Shares: +20.80%2025-06-30 → 2026-06-30255.5M → 308.6M (+20.8% total)+12.05%2023-06-30 → 2026-06-30219.4M → 308.6M (+40.7% total)+26.77%2021-03-31 → 2026-06-3088.9M → 308.6M (+247.3% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +18.25%2025-06-30 → 2026-06-30$41.98 → $49.63 (+18.2% total)+29.92%2023-06-30 → 2026-06-30$22.63 → $49.63 (+119.3% total)+40.36%2021-03-31 → 2026-06-30$8.37 → $49.63 (+492.8% total)n/a
FCF/share: +202.01%2025-06-30 → 2026-06-30$4.70 → $14.19 (+201.8% total)+172.64%2023-06-30 → 2026-06-30$0.70 → $14.19 (+1927.9% total)+23.45%2021-03-31 → 2026-06-30$4.70 → $14.19 (+202.1% total)n/a
Book value/share: +46.70%2025-06-30 → 2026-06-30$4.53 → $6.65 (+46.7% total)+15.37%2023-06-30 → 2026-06-30$4.33 → $6.65 (+53.6% total)-19.01%2021-03-31 → 2026-06-30$20.10 → $6.65 (-66.9% total)n/a
Price: +51.68%2025-10-16 → 2026-10-16$21.03 → $31.89 (+51.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+85.18%2023-10-16 → 2026-10-16$5.02 → $31.89 (+535.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.00%2021-10-15 → 2026-10-16$15.85 → $31.89 (+101.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +51.68%2025-10-16 → 2026-10-16$21.03 → $31.89 (+51.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+85.18%2023-10-16 → 2026-10-16$5.02 → $31.89 (+535.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.00%2021-10-15 → 2026-10-16$15.85 → $31.89 (+101.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 17.5×2021-03 -5.992026-10 17.87-398.4% over the window
Fwd P/E: 15.2×
P/S (ttm)Market cap ÷ TTM revenue.: 0.6×2021-03 3.212026-10 0.64-80.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.8×2021-03 1.342026-10 4.80+258.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 2.2×2021-03 5.722026-10 2.25-60.7% over the window
EV/EBITDA (fy): 9.5×
EV/Sales (ttm): 0.4×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 44.50%2020-12 8.7%2026-06 49.8%+469.5% over the window
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($9.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2020-12 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($9.8B). Same caveat as the cash buyback yield.: 0.00%2020-12 0.0%2026-06 0.0%

Vs own 10Y history

P/S: 66th
P/B: 90th
P/FCF: 11th

Bar = where today’s multiple sits in OSCR’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-4.72%

-4.44%

-1.39%

+10.50%

YTD

+121.92%

+51.64%

+101.20%

Recent filings#

Aug 28Insider sale · Schlosser Mario (Director) sold 750,000 Class A shares for $22.8M on 2 days since Aug 27
Aug 18Insider sale · Blackley Richard Scott (Chief Financial Officer) sold 18,750 Class A shares for $595K at $31.74
Aug 6Earnings · Earnings release — EPS $1.10 vs $0.43 est. (+155.8%); revenue $4.88B (+70% y/y) 11.9%

All filings and insider trades →

Financial statements

Open full OSCR financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

OSCR — Oscar Health Inc. price, chart and key statistics